Omega Therapeutics presents preclinical data on liver fibrosis and inflammation

Omega Therapeutics announced the presentation of new preclinical data from two different programs that demonstrated sustained upregulation of gene expression and coordinated pre-transcriptional downregulation of multiple genes in models of liver fibrosis and inflammation, respectively, at the American Association for the Study of Liver Diseases’ The Liver Meeting 2023, taking place in Boston, November 10 – 14. Single administration of an EC in the humanized FRG mouse model resulted in induction of HNF4alpha mRNA levels compared to untreated FRG mice. EC-mediated induction of HNF4alpha expression in vivo in a mouse model of liver fibrosis led to decreased collagen deposition, a key marker of fibrosis. Treatment of mouse and human liver cells with ECs engineered to pre-transcriptionally downregulate the expression CXCL9, CXCL10 and CXCL11 resulted in robust mRNA downregulation and decreased protein levels of all three chemokines. Primary human hepatocytes stimulated with interferon gamma and treated with a single EC targeting CXCL9-11 resulted in a statistically significant decrease in mRNA expression and protein levels of each chemokine compared to INFG stimulation alone.